ONL logo.jpg
ONL Therapeutics Appoints Sushanta Mallick as Chief Development Officer
February 09, 2022 07:00 ET | ONL Therapeutics
ANN ARBOR, Mich., Feb. 09, 2022 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal...
Adverum Mails Letter to Stockholders Highlighting World-Class Board of Directors Overseeing Successful ADVM-022 Commercial Launch
April 21, 2021 08:00 ET | Adverum Biotechnologies, Inc.
Sonic’s Nominees Lack Experience and Qualifications to Advance Adverum’s Commercialization Progress or Deliver Global Access to Vision-Saving Gene Therapy Urges Stockholders to Vote the WHITE Proxy...
Logo.jpg
Adverum Appoints Christopher J. DeRespino as Chief Business Officer
February 18, 2021 16:00 ET | Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases,...
ONL logo.jpg
ONL Therapeutics Names Connie Chang as Chief Operating Officer
January 19, 2021 07:00 ET | ONL Therapeutics
ANN ARBOR, Mich., Jan. 19, 2021 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today...
ONL logo.jpg
ONL Therapeutics Closes $46.9 Million in Series B Financing to Advance ONL1204 into Three Retinal Disease Indications
December 22, 2020 07:00 ET | ONL Therapeutics
ANN ARBOR, Mich., Dec. 22, 2020 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today...
ONL Therapeutics Announces First Patient Treated in Phase I Study with ONL1204
October 23, 2019 07:00 ET | ONL Therapeutics
ANN ARBOR, Mich., Oct. 23, 2019 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today...
ONL Therapeutics Announces First-In-Human Clinical Study with ONL1204
October 08, 2019 07:00 ET | ONL Therapeutics
Lead candidate ONL1204 advances into Phase I clinical study in retinal detachment in Australia ANN ARBOR, Mich., Oct. 08, 2019 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a biopharmaceutical...
ONL Therapeutics Raises $3 Million in a Convertible Note to Advance ONL1204 into First-In-Human Clinical Study
August 22, 2019 11:54 ET | ONL Therapeutics
ANN ARBOR, Mich., Aug. 22, 2019 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today...
ONL Therapeutics Raises $3 Million in a Convertible Note to Advance ONL1204 into First-In-Human Clinical Study
August 22, 2019 07:00 ET | ONL Therapeutics
ANN ARBOR, Mich., Aug. 22, 2019 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today...
ONL Therapeutics Names Industry Veteran as CEO as Company Prepares for First in Human Clinical Trials
June 18, 2019 07:00 ET | ONL Therapeutics
ANN ARBOR, Mich., June 18, 2019 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for preserving vision in a range of retinal diseases, today...